JP2005510535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005510535A5 JP2005510535A5 JP2003546836A JP2003546836A JP2005510535A5 JP 2005510535 A5 JP2005510535 A5 JP 2005510535A5 JP 2003546836 A JP2003546836 A JP 2003546836A JP 2003546836 A JP2003546836 A JP 2003546836A JP 2005510535 A5 JP2005510535 A5 JP 2005510535A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery agent
- dosage form
- cromolyn sodium
- mass
- cromolyn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000265 cromoglicic acid Drugs 0.000 claims description 51
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 18
- 229960001340 histamine Drugs 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 7
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 49
- 229940124447 delivery agent Drugs 0.000 claims 32
- 239000006186 oral dosage form Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 19
- 102000004127 Cytokines Human genes 0.000 claims 7
- 108090000695 Cytokines Proteins 0.000 claims 7
- 210000003630 histaminocyte Anatomy 0.000 claims 7
- 238000010521 absorption reaction Methods 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000008184 oral solid dosage form Substances 0.000 claims 1
- 229940100692 oral suspension Drugs 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- -1 pyrrolo Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 4
- 208000024780 Urticaria Diseases 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 description 3
- 239000013566 allergen Substances 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33439501P | 2001-11-29 | 2001-11-29 | |
| US60/334,395 | 2001-11-29 | ||
| US38491602P | 2002-05-24 | 2002-05-24 | |
| US60/384,916 | 2002-05-24 | ||
| PCT/US2002/038247 WO2003045331A2 (en) | 2001-11-29 | 2002-11-29 | Formulations for oral administration of cromolyn sodium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005510535A JP2005510535A (ja) | 2005-04-21 |
| JP2005510535A5 true JP2005510535A5 (https=) | 2006-02-02 |
| JP5196701B2 JP5196701B2 (ja) | 2013-05-15 |
Family
ID=26989179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546836A Expired - Fee Related JP5196701B2 (ja) | 2001-11-29 | 2002-11-29 | クロモリンナトリウムの経口投与用製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20040259952A1 (https=) |
| EP (1) | EP1461031B1 (https=) |
| JP (1) | JP5196701B2 (https=) |
| AU (1) | AU2002352974A1 (https=) |
| CA (1) | CA2466863A1 (https=) |
| WO (1) | WO2003045331A2 (https=) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050209141A1 (en) * | 2003-10-17 | 2005-09-22 | Silver Randi B | Mast cell-derived renin |
| KR20060134216A (ko) | 2004-04-16 | 2006-12-27 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염 |
| MXPA06013252A (es) * | 2004-05-14 | 2007-02-28 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
| CN1968704B (zh) * | 2004-05-19 | 2010-12-08 | 爱密斯菲尔科技公司 | 局部用色甘酸制剂 |
| BRPI0510820A (pt) | 2004-05-19 | 2007-11-27 | Emisphere Tech Inc | composição farmacêutica, forma unitária de dosagem e seus usos |
| AU2005321803B2 (en) | 2004-12-29 | 2012-02-09 | Emisphere Technologies, Inc. | Pharmaceutical formulations of gallium salts |
| US8110547B2 (en) | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| JP4558045B2 (ja) * | 2005-11-01 | 2010-10-06 | 株式会社リバース・プロテオミクス研究所 | アレルギー疾患の治療に有用な化合物をスクリーニングする方法 |
| GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US20070249727A1 (en) | 2006-04-21 | 2007-10-25 | The Proctor & Gamble Company | Compositions and kits useful for treatment of respiratory illness |
| JP5475443B2 (ja) | 2006-06-28 | 2014-04-16 | エミスフェアー・テクノロジーズ・インク | 硝酸ガリウム製剤 |
| US8445437B2 (en) * | 2006-07-27 | 2013-05-21 | The Brigham And Women's Hospital, Inc. | Treatment and prevention of cardiovascular disease using mast cell stabilizers |
| CN101808642B (zh) | 2007-09-28 | 2012-05-02 | 布里格海姆妇女医院公司 | 肥大细胞稳定剂治疗肥胖症 |
| US10517839B2 (en) * | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US8617517B2 (en) | 2009-01-29 | 2013-12-31 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| US20110039930A1 (en) | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| US8843456B2 (en) | 2011-12-06 | 2014-09-23 | International Business Machines Corporation | Database table compression |
| HRP20181447T1 (hr) | 2012-03-22 | 2018-11-02 | Novo Nordisk A/S | Pripravci glp-1 peptida i njihova priprava |
| PT2827845T (pt) | 2012-03-22 | 2019-03-29 | Novo Nordisk As | Composições compreendendo um agente de entrega e sua preparação |
| ES2965469T3 (es) | 2012-03-22 | 2024-04-15 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y preparación de estas |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| EP3563849A3 (en) | 2012-10-25 | 2020-02-12 | The General Hospital Corporation | Combination therapies for the treatment of alzheimer's disease and related disorders |
| US20160082075A1 (en) * | 2013-03-27 | 2016-03-24 | Scpharmaceuticals Inc. | Combination Therapy for Subcutaneous Administration of Glycopeptide Antibiotics |
| KR102272671B1 (ko) | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| CN110305095A (zh) | 2013-10-22 | 2019-10-08 | 综合医院公司 | 色甘酸衍生物以及成像和治疗的相关方法 |
| WO2015070116A2 (en) * | 2013-11-11 | 2015-05-14 | Harish Ziv M D | Formulations and methods for prevention and treatment of oral allergy syndrome |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| ES2792682T3 (es) | 2014-02-10 | 2020-11-11 | Respivant Sciences Gmbh | Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos |
| US20180036382A1 (en) | 2015-02-09 | 2018-02-08 | Entera Bio Ltd. | Formulations for oral administration of active agents with controlled absorption profile |
| US10238625B2 (en) | 2015-08-07 | 2019-03-26 | Respivant Sciences Gmbh | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| BR112018071518A2 (pt) | 2016-04-22 | 2019-02-19 | Receptor Life Sciences, Inc. | compostos medicinais à base de planta de ação rápida e suplementos nutricionais |
| CN116850132A (zh) | 2016-08-17 | 2023-10-10 | 安提拉生物有限公司 | 用于口服的活性剂的制剂 |
| WO2018044942A1 (en) * | 2016-08-31 | 2018-03-08 | Patara Pharma, LLC | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
| JP2019524865A (ja) | 2016-08-31 | 2019-09-05 | ザ ジェネラル ホスピタル コーポレイション | 神経変性疾患と関連する神経炎症におけるマクロファージ／ミクログリア |
| EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| US20190336472A1 (en) * | 2017-01-03 | 2019-11-07 | Receptor Holdings, Inc. | Medicinal compounds and nutritional supplements |
| JP7202376B2 (ja) | 2017-07-20 | 2023-01-11 | エーゼットセラピーズ， インコーポレイテッド | クロモリンナトリウムおよびイブプロフェンの粉末製剤 |
| CN111629719A (zh) * | 2017-12-04 | 2020-09-04 | 通用医疗公司 | 色甘酸组合物及其方法 |
| JP6898518B2 (ja) | 2018-02-02 | 2021-07-07 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物 |
| AU2019299347A1 (en) | 2018-07-02 | 2021-01-21 | Aztherapies, Inc. | Powdered formulations of cromolyn sodium and alpha-lactose |
| UA122811C2 (uk) * | 2018-08-10 | 2021-01-06 | Наталія Миколаївна Тихонівська | Фармацевтична композиція |
| WO2020097686A1 (en) * | 2018-11-14 | 2020-05-22 | Holman Pharmaceuticals Pty Ltd | Compositions and uses thereof |
| EP3883595A4 (en) | 2018-11-19 | 2022-12-14 | Receptor Holdings, Inc. | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID-BASED COMPOSITIONS |
| MX2021006869A (es) | 2018-12-10 | 2021-07-02 | Massachusetts Gen Hospital | Esteres de cromolin y usos de los mismos. |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
| WO2022146914A1 (en) | 2020-12-28 | 2022-07-07 | The General Hospital Corporation | Cromolyn derivatives and uses thereof |
| US11986492B2 (en) * | 2022-09-21 | 2024-05-21 | Ashley Wolchina Allison | Oral supplement for preventing colic in horses |
| CN116509836A (zh) * | 2023-03-23 | 2023-08-01 | 中山万汉制药有限公司 | 色甘酸钠－季铵盐复合物及其制备方法与用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6281380A (ja) * | 1985-10-04 | 1987-04-14 | Kyoto Yakuhin Kogyo Kk | クロモグリク酸誘導体、その製造法および抗アレルギ−剤 |
| US5447728A (en) | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| JPH06281380A (ja) | 1993-03-26 | 1994-10-07 | Hisaka Works Ltd | プレート式熱交換器用ガスケット |
| US5643957A (en) * | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU6819294A (en) * | 1993-04-22 | 1994-11-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US6201011B1 (en) * | 1996-08-30 | 2001-03-13 | Kyoto Pharmaceutical Industries, Ltd. | Therapeutic agent for allergic dermatitis |
| ATE383169T1 (de) | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
| US5888529A (en) * | 1997-03-28 | 1999-03-30 | The Regents Of The University Of California | Ileus treatment method |
| US5863944A (en) * | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5952353A (en) * | 1997-09-19 | 1999-09-14 | Auburn University | Treating/preventing heart failure via inhibition of mast cell degranulation |
| ATE429210T1 (de) * | 1998-01-20 | 2009-05-15 | Applied Analytical Ind Inc | Orale flüssige zusammensetzungen |
| JP5144861B2 (ja) * | 1998-07-27 | 2013-02-13 | エミスフェアー・テクノロジーズ・インク | 活性剤のデリバリーのための化合物及び組成物 |
| IL140930A0 (en) * | 1998-08-07 | 2002-02-10 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
| GB9824604D0 (en) * | 1998-11-11 | 1999-01-06 | Hewlett Healthcare Limited | Treatment of allergic conditions |
| MXPA01008611A (es) * | 1999-02-26 | 2003-06-24 | Emisphere Tech Inc | Compuestos y composiciones para suministrar agentes activos. |
| ES2235854T3 (es) | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
| MXPA02004092A (es) * | 1999-11-05 | 2003-02-12 | Emisphere Tech Inc | Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos. |
| ES2298168T3 (es) * | 1999-12-16 | 2008-05-16 | Emisphere Technologies, Inc. | Compuestos y composiciones para suministrar agentes activos. |
| CA2292902C (en) * | 1999-12-24 | 2012-12-18 | Alain Cadieux | Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases |
| US7151191B2 (en) * | 2000-01-13 | 2006-12-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6225356B1 (en) * | 2000-01-20 | 2001-05-01 | Jones, Iii Tudor | Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea |
| WO2001060413A2 (en) * | 2000-02-15 | 2001-08-23 | Board Of Trustees Of The University Of Arkansas | Recombinant vector expressing a beta2-adrenergic receptor and use in treating airway and vascular diseases |
| ES2306719T3 (es) * | 2000-06-29 | 2008-11-16 | Emisphere Technologies, Inc. | Compuestos y composiciones para la administracion de principios activos. |
| AU2002211805A1 (en) * | 2000-09-06 | 2002-03-22 | Emisphere Technologies, Inc. | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents |
-
2002
- 2002-11-29 CA CA002466863A patent/CA2466863A1/en not_active Abandoned
- 2002-11-29 EP EP02789934.3A patent/EP1461031B1/en not_active Expired - Lifetime
- 2002-11-29 WO PCT/US2002/038247 patent/WO2003045331A2/en not_active Ceased
- 2002-11-29 JP JP2003546836A patent/JP5196701B2/ja not_active Expired - Fee Related
- 2002-11-29 US US10/497,286 patent/US20040259952A1/en not_active Abandoned
- 2002-11-29 AU AU2002352974A patent/AU2002352974A1/en not_active Abandoned
-
2008
- 2008-04-16 US US12/103,821 patent/US8513300B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005510535A5 (https=) | ||
| US20150272934A1 (en) | Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders | |
| JPS6143112A (ja) | 精神性欲機能障害治療剤 | |
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JP2005515966A5 (https=) | ||
| JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| CA3043028A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| US20220151960A1 (en) | Treatment of symptoms associated with female gastroparesis | |
| JP2012533559A (ja) | アセトアミノフェンの治療効果を改善するためのｎ−アセチルシステイン組成物および方法 | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| CA2688542C (en) | Methods and compositions for administration of oxybutynin | |
| JP2024527023A5 (https=) | ||
| JP2005512946A5 (https=) | ||
| US20100105685A1 (en) | S-Nitrosothiol Compounds and Related Derivatives | |
| US20240408004A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| US20200390691A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| CN115607545B (zh) | 依达拉奉在自闭症谱系障碍治疗中的应用 | |
| WO2020132263A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| EP4218750A1 (en) | The use of melanin in therapy of subjects with trisomy 21 | |
| WO2026013001A1 (en) | Phosphatidylinositol 4-kinase beta inhibitor compositions for treating human rhinovirus infection | |
| JPH01501708A (ja) | アミノ酸の経鼻投与 | |
| JP2004175786A (ja) | Ｉ型アレルギー疾患治療用組成物 |